Genome-Wide Transcriptome Analysis in Type 2 Diabetes Patients Treated by Sitagliptin

References

• Tahrani AA, Piya MK, Kennedy A, Barnett AH. Glycaemic control in type 2 diabetes: targets and new therapies. Pharmacol Ther. 2010;125(2):328–361. doi:10.1016/j.pharmthera.2009.11.001
   PubMed Web of Science ®Google Scholar
• Lu JM. Based on the consensus of clinical application of glucagon-like peptide 1 hypoglycemic drugs. Chin J Diabetes. 2014;6(01):14–20.
   Google Scholar
• Scott LJ. Sitagliptin: a review in type 2 diabetes. Drugs. 2017;77(2):209–224. doi:10.1007/s40265-016-0686-9
   PubMed Web of Science ®Google Scholar
• Ji L, Han P, Wang X, et al. Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co-administered to Chinese patients with type 2 diabetes mellitus. J Diabetes Investig. 2016;7(5):727–736. doi:10.1111/jdi.12511
   Web of Science ®Google Scholar
• Ji L, Li L, Kuang J, et al. Efficacy and safety of fixed-dose combination therapy, alogliptin plus metformin, in Asian patients with type 2 diabetes: a Phase 3 trial. Diabetes Obes Metab. 2017;19(5):754–758. doi:10.1111/dom.12875
   Web of Science ®Google Scholar
• Mohan V, Yang W, Son HY, et al. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract. 2009;83(1):106–116. doi:10.1016/j.diabres.2008.10.009
   PubMed Web of Science ®Google Scholar
• Pan CY, Yang W, Tou C, Gause-Nilsson I, Zhao J. Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Metab Res Rev. 2012;28(3):268–275. doi:10.1002/dmrr.1306
   PubMed Web of Science ®Google Scholar
• Wu W, Li Y, Chen X, et al. Effect of linagliptin on glycemic control in Chinese patients with newly-diagnosed, drug-naïve type 2 diabetes mellitus: a randomized controlled trial. Med Sci Monit. 2015;21:2678–2684. doi:10.12659/MSM.894026
   Web of Science ®Google Scholar
• Pan C, Han P, Ji Q, et al. Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: a multicentre randomized double-blind placebo-controlled phase 3 study in mainland China, Taiwan, and Hong Kong. J Diabetes. 2017;9(4):386–395. doi:10.1111/1753-0407.12425
   Web of Science ®Google Scholar
• Ba J, Han P, Yuan G, et al. Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin. J Diabetes. 2017;9(7):667–676. doi:10.1111/1753-0407.12456
   Web of Science ®Google Scholar
• Wang W, Ning G, Ma J, et al. A randomized clinical trial of the safety and efficacy of sitagliptin in patients with type 2 diabetes mellitus inadequately controlled by acarbose alone. Curr Med Res Opin. 2017;33(4):693–699. doi:10.1080/03007995.2016.1277200
   PubMed Web of Science ®Google Scholar
• Yang W, Guan Y, Shentu Y, et al. The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes. J Diabetes. 2012;4(3):227–237. doi:10.1111/j.1753-0407.2012.00213.x
   Web of Science ®Google Scholar
• Yang W, Pan CY, Tou C, Zhao J, Gause-Nilsson I. Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Res Clin Pract. 2011;94(2):217–224. doi:10.1016/j.diabres.2011.07.035
   Web of Science ®Google Scholar
• Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS, Cho YM. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia. 2013;56(4):696–708. doi:10.1007/s00125-012-2827-3
   PubMed Web of Science ®Google Scholar
• Nomiyama T, Akehi Y, Takenoshita H, et al. Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2012;95(2):e27–e28. doi:10.1016/j.diabres.2011.08.016
   PubMed Web of Science ®Google Scholar
• Liao Y, Wu XW, Feng LL, et al. A research method for the influencing factors of the efficacy of sitagliptin: study group mean value extraction and statistical inference. Chin J Hosp Pharm. 2019;39(06):570–576. Chinese.
   Google Scholar
• Bonora E, Kiechl S, Willeit J, et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes. 1998;47(10):1643–1649.
   PubMed Web of Science ®Google Scholar
• Sekar N, Veldhuis JD. Concerted transcriptional activation of the low density lipoprotein receptor gene by insulin and luteinizing hormone in cultured porcine granulosa-luteal cells: possible convergence of protein kinase a, phosphatidylinositol 3-kinase, and mitogen-activated protein kinase signaling pathways. Endocrinology. 2001;142(7):2921–2928. doi:10.1210/endo.142.7.8287
   Web of Science ®Google Scholar
• Dunaif A, Wu X, Lee A, Diamanti-Kandarakis E. Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). Am J Physiol Endocrinol Metab. 2001;281(2):E392–E399. doi:10.1152/ajpendo.2001.281.2.E392
   PubMed Web of Science ®Google Scholar
• Ciaraldi TP, el-Roeiy A, Madar Z, Reichart D, Olefsky JM, Yen SS. Cellular mechanisms of insulin resistance in polycystic ovarian syndrome. J Clin Endocrinol Metab. 1992;75(2):577–583. doi:10.1210/jcem.75.2.1322430
   PubMed Web of Science ®Google Scholar
• Li YX, Hong YZ. Mechanism and therapeutic progress of SOCS-3 in insulin resistance. China Modern Doctor. 2006;12(54):163–168.
   Google Scholar
• Wang NH, Guo XH. SOCS-3 and insulin resistance. Int J Endocrinol Metab. 2005;06:409–411.
   Google Scholar
• Ueki K, Kondo T, Kahn CR. Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol. 2004;24(12):5434–5446. doi:10.1128/MCB.24.12.5434-5446.2004
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zhang Q, Soderland C, Steinle JJ. TNFα and SOCS3 regulate IRS-1 to increase retinal endothelial cell apoptosis. Cell Signal. 2012;24(5):1086–1092. doi:10.1016/j.cellsig.2012.01.003
   Web of Science ®Google Scholar
• Lebrun P, Cognard E, Bellon-Paul R, et al. Constitutive expression of suppressor of cytokine signalling-3 in skeletal muscle leads to reduced mobility and overweight in mice. Diabetologia. 2009;52(10):2201–2212. doi:10.1007/s00125-009-1474-9
   Web of Science ®Google Scholar
• Stern MP. Diabetes and cardiovascular disease. The “common soil” hypothesis. Diabetes. 1995;44(4):369–374. doi:10.2337/diab.44.4.369
   PubMed Web of Science ®Google Scholar